This review provides clinical guidance on the use of biomarkers such as natriuretic peptides, troponins, sST2, and galectin-3 in the management of heart failure.
Biomarkers enable objective HF assessment; supports clinical integration but leaves open prospective validation before guideline changes.
Objective, noninvasive, clinical assessment of patients with heart failure can be made using biomarker measurements, including natriuretic peptides, cardiac troponins, soluble suppression of tumorigenicity 2, and galectin-3. The aim of this review is to provide clinicians with guidance on the use of heart failure biomarkers in clinical practice. The authors provide a didactic narrative based on current literature, an exemplary case study, and their clinical experience.
No takes yet. Share an insight, caveat, or question.
Paul et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: